Not a good buy right now for an impatient investor: the trend is still bearish (SMA_200 > SMA_20 > SMA_5) and there’s no strong catalyst to force a quick upside move.
Price (pre-market 4.04) is sitting just above key support (S1 4.028). That can produce a short bounce, but the overhead pivot/resistance (4.28–4.53) limits near-term upside unless momentum improves.
With no Intellectia buy signals today (AI Stock Picker and SwingMax both inactive), there’s no high-conviction tactical edge for immediate entry.
Overall stance: wait/hold (do not initiate a new buy here).
Momentum: MACD histogram is positive (0.0602) but “positively contracting,” implying bullish momentum is weakening rather than accelerating.
RSI (6): ~40 (neutral-to-soft). Not oversold enough to signal a strong mean-reversion buy.
Key levels: Support S1 4.028 (price 4.04 is barely above), then S2 3.872. Resistance/pivot at 4.28, then R1 4.532 and R2 4.688.
Pattern-based expectation: Similar-pattern stats suggest modest upside potential over a month (+3.5%), but near-term is weak (next week -0.78% expected), which doesn’t fit an “buy now for quick move” profile.
can trigger a technical bounce if buyers defend the level.
Neutral/Negative Catalysts
Primary technical setup remains bearish (downtrend by moving averages), which is unfavorable for immediate buying.
Analyst downgrade to Hold (linked to reverse split mechanics) is a sentiment headwind and often reduces near-term demand.
Lack of fresh catalysts/newsflow reduces the odds of a fast upside breakout.
Business fundamentals show very small revenue and continuing losses (see latest quarter), which typically limits sustained rallies.
Positioning signals: Hedge funds and insiders are neutral—no visible “smart money” accumulation signal.
Financial Performance
Latest provided quarter: 2023/Q4.
Revenue: 155,000 (reported as up 0.00% YoY in the snapshot) — extremely small scale.
Profitability: Net income -1,652,000; EPS -4.29 — ongoing losses.
Gross margin: 100 (as reported) — despite margin, the operating scale is too small and losses persist.
Growth takeaway: The data does not show meaningful growth acceleration; the company remains loss-making, which weakens the case for an “immediate buy.”
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: On 2025-12-24, D. Boral Capital analyst Jason Kolbert downgraded CANF to Hold from Buy with no price target, citing the board-approved reverse split/ADS ratio change and firm policy ahead of split execution.
Wall Street pro view (pros): Prior coverage had been constructive (previous Buy), implying some belief in the story, but that support is not active right now.
Wall Street con view (cons): The downgrade and removal of a price target reduce conviction and often pressure near-term demand.
Politicians/influential trading: No recent congress trading data available; no politician/influential buy/sell signal is provided in the dataset.
Congress trading (last 90 days): No recent congress trading data available.
Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.5 USD with a low forecast of 2.5 USD and a high forecast of 2.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.5 USD with a low forecast of 2.5 USD and a high forecast of 2.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.250
Low
2.5
Averages
2.5
High
2.5
Current: 4.250
Low
2.5
Averages
2.5
High
2.5
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
AI Analysis
2025-12-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2025-12-24
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma to Hold from Buy with no price target after the company's board approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio. The firm is lowering its rating ahead of the actual split, consistent with its policy, the analyst noted.
H.C. Wainwright
H.C. Wainwright
initiated
$2.50
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$2.50
2025-11-04
initiated
Reason
H.C. Wainwright assumed coverage of Can-Fite BioPharma with a Buy rating and $2.50 price target. The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CANF
